Oncology Molecular Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Oncology Molecular Diagnostics Market Trends and Insights

Uptake of Liquid-Biopsy Companion Diagnostics

FDA approvals for liquid biopsy companion diagnostics have multiplied since 2023, enabling real-time genomic monitoring without invasive tissue sampling. FoundationOne Liquid CDx now guides MET exon 14 skipping therapy in non-small cell lung cancer, expanding precision care to patients with limited tissue.^{[1]Foundation Medicine Editorial Team, “FoundationOne Liquid CDx Receives New FDA Approval,” Foundation Medicine, foundationmedicine.com}

Between 2024 and 2025, ctDNA assays received FDA breakthrough status for EGFR, ALK, and KRAS G12C mutations, reinforcing liquid biopsy as a key alternative to traditional tissue genotyping. The turnaround time for these assays has been reduced to 3–5 business days, enabling faster decisions on targeted therapies during the critical first-line treatment phase. AstraZeneca’s FLAURA2 trial leveraged plasma selection to cut enrolment time by 22%, leading to osimertinib approval in August 2024. However, reimbursement challenges persist in emerging markets; for example, in India, public health plans continue to exclude ctDNA, restricting its adoption primarily to private payors.

National Genomics Reimbursement Initiatives

Programs such as Australia’s PrOSPeCT offer 23,000 patients free genomic testing funded by USD 185 million, demonstrating how coordinated policy, clinical trial access, and coverage decisions converge to democratize precision oncology.^{[2]UNSW Media Office, “PrOSPeCT to Deliver Genomic Testing for 23,000 Australians,” UNSW, unsw.edu.au} In January 2025, Medicare established a rate of USD 3,200 for panels covering 324 genes, streamlining the process by eliminating prior-authorization delays that previously lasted up to 3 weeks. By December 2025, Japan plans to reimburse NGS panels at JPY 560,000 (equivalent to USD 3,800), enhancing access to 58 primary hospitals. In 2024, the United Kingdom allocated GBP 175 million to expand whole-genome sequencing to 100,000 cancer patients annually by 2027. Collectively, these measures address significant cost barriers, driving growth and expanding the oncology molecular diagnostics market footprint.

Rising Prevalence of Cancer

In 2024, the global incidence of new cancer cases reached 20 million, reflecting a 7.8% increase from 2020.^{[3]International Agency for Research on Cancer, “GLOBOCAN 2024,” iarc.fr} This growth has driven the demand for molecular profiling to support personalized therapies. Lung cancer alone accounted for 2.5 million of these new diagnoses, boosting the need for assays targeting EGFR, ALK, ROS1, and BRAF. In the United States, 154,000 colorectal cancer cases are projected for 2025, emphasizing the importance of earlier, molecularly-guided screenings. Meanwhile, China reported 4.8 million new cancer cases in 2024 and is allocating resources to hepatitis-B and H. pylori control programs, which rely on PCR-based detection.

Increasing Demand for Point-of-Care Molecular Testing

In February 2025, Cepheid introduced the GeneXpert Xpress EGFR, capable of delivering mutation results within 90 minutes using a finger-stick sample. India implemented 42 GeneXpert systems across tier-2 cities, significantly reducing the median time for treatment initiation from 28 days to just 9 days for patients with EGFR-positive lung cancer. Additionally, Bio-Rad launched the QX600 AutoDG in August 2025, reducing droplet-generation time to 15 minutes and enabling same-day ctDNA quantification. These advancements collectively enhance oncology testing capabilities in outpatient settings and rural clinics.

High Cost of Molecular Diagnostic Tests

In the United States, comprehensive gene panels, covering 300 to 500 genes, are priced between USD 3,000 and 5,800. This pricing leaves under-insured patients facing out-of-pocket fees of USD 1,500, even after coverage adjustments. A 2024 study revealed that 23% of eligible stage IV lung-cancer patients declined testing due to cost concerns. This decision led to a 6.2-week delay in therapy initiation and a reduction of 1.8 months in progression-free survival. In India, the cost of tests, ranging from 80,000 to 150,000 INR (approximately USD 960 to 1,800), represents four to eight months of household income. This financial burden limits access primarily to urban centers. In Brazil, the exclusion of comprehensive profiling from the national health plan confines such services largely to private hospitals.

Shortage of Genomic Pathologists

In 2025, the United States faced a significant shortage of 1,200 board-certified molecular genetic pathologists. Despite a demand for approximately 190 fellows annually, only 87 graduated in 2024. Report turnaround times at community sites can take up to 2 weeks, delaying therapy compared to large academic centers that streamline processes through in-house tumor boards. In India, the National Cancer Grid launched a fellowship program in July 2025, aiming to train 50 fellows annually. However, this initiative is projected to meet only 18% of the required demand through 2030. While AI annotation tools have reduced manual review time by 60%, regulatory frameworks for autonomous sign-outs remain undefined.

*Our updated forecasts treat driver/restraint impacts as directional, not additive. The revised impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Services Surge on Bioinformatics Demand

Reagents and consumables generated 61.55% revenue in 2025, reflecting recurrent demand and proprietary chemistries that capture low-abundance mutations. This strong position anchors steady cash flows for manufacturers within the oncology molecular diagnostics market. Software and services, although smaller today, rise at a 15.21% CAGR as cloud-hosted analytics automate interpretation and reduce the need for scarce genomic pathologists.

Growth in AI-powered platforms positions bioinformatics as a strategic moat. Vendors bundling reagents with subscription-based interpretation tools secure end-to-end integration, fostering customer stickiness. The oncology molecular diagnostics software solutions market size is projected to expand markedly as laboratories seek efficiency gains and standardized reporting.

Note: Segment shares of all individual segments available upon report purchase

By Technology: NGS Gains as Panel Costs Decline

PCR delivered 34.62% revenue in 2025 as laboratories value its cost efficiency and reliability. Digital PCR further extends sensitivity for detecting rare variants in liquid biopsy. In parallel, next-generation sequencing enjoys a 13.5% CAGR, propelled by declining run costs and broader clinical utility. Hybrid capture panels detect hundreds of genes in one assay, transforming treatment selection.

NGS adoption also benefits from combined tissue and plasma workflows that reveal tumor heterogeneity. As laboratories validate liquid biopsy NGS panels, the oncology molecular diagnostics market size for comprehensive profiling grows faster than single-gene PCR assays, yet PCR remains indispensable for rapid single-mutation confirmation.

By Cancer Type: Lung Surges on Liquid-Biopsy Adoption

Breast cancer testing contributed 17.84% of 2025 revenue, sustained by established biomarkers such as HER2 and estrogen receptors. Routine testing ensures consistent volume and underpins reagent consumption in the oncology molecular diagnostics market. Lung cancer, however, records the highest 12.71% CAGR thanks to extensive biomarker panels that include EGFR, ALK, ROS1, and KRAS mutations.

Liquid biopsy companion diagnostics for lung cancer remove tissue constraints, broadening eligible patient pools. Consequently, the oncology molecular diagnostics market share of lung cancer assays is projected to narrow the gap with breast cancer, driven by payer coverage and inclusion in clinical guidelines.

Note: Segment shares of all individual segments available upon report purchase

By Sample Type: Liquid Biopsy Climbs on MRD Utility

Tissue biopsy retained 70.62% share in 2025, remaining the histopathological gold standard for initial diagnosis. Yet liquid biopsy revenue climbs at a 14.14% CAGR as non-invasive blood tests facilitate continuous monitoring. Regulatory approvals establish clinical confidence, and patients prefer serial blood draws over repeat tissue procedures.

Serial molecular monitoring detects emerging resistance sooner than imaging, an advantage that fuels adoption. As laboratories standardize circulating tumor DNA workflows, the oncology molecular diagnostics market size for liquid biopsy is set to rise in parallel with expanding companion diagnostic indications.

By End User: Point-of-Care Expands on Portable Devices

Hospitals and academic centers generated 54.86% revenue in 2025, aided by advanced infrastructure and multidisciplinary teams. Yet point-of-care locations register a 13.02% CAGR as cartridge-based platforms simplify testing. Community oncologists gain timely genomic insights without sending samples to central labs.

The trend aligns with value-based care goals that favor rapid decision making. Vendors offering compact analyzers with integrated bioinformatics will capture share as the oncology molecular diagnostics market shifts toward patient-centric delivery models.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America accounted for 39.72% of revenue in 2025, leveraging early regulatory approvals and broad insurance coverage for comprehensive genomic profiling. Testing rates for actionable biomarkers approach 90% in leading cancer centers. Expanded Medicare coverage for minimal residual disease tracking further enlarges the oncology molecular diagnostics market.

Europe adopts a cost-effectiveness lens, leading to selective uptake but consistent reimbursement once clinical utility is proven. Harmonized companion diagnostic and drug approvals by the European Medicines Agency ensure synchronized market entry, supporting stable growth moderated by budget impact assessments.

Asia-Pacific posts the fastest 15.89% CAGR, supported by China’s precision medicine plan and Japan’s genomic cancer program. Investments in national sequencing networks and public-private partnerships lower per-test costs and accelerate technology transfer. As local innovators refine assays for region-specific mutations, the oncology molecular diagnostics market in Asia-Pacific is expanding rapidly, driven by rising cancer incidence and improving healthcare infrastructure.